Annie Guérin
About
Annie Guérin is a scholar working on Hematology, Genetics and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Annie Guérin has authored 220 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Hematology, 50 papers in Genetics and 41 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Annie Guérin's work include Chronic Myeloid Leukemia Treatments (43 papers), Chronic Lymphocytic Leukemia Research (42 papers) and Acute Lymphoblastic Leukemia research (18 papers). Annie Guérin is often cited by papers focused on Chronic Myeloid Leukemia Treatments (43 papers), Chronic Lymphocytic Leukemia Research (42 papers) and Acute Lymphoblastic Leukemia research (18 papers). Annie Guérin collaborates with scholars based in United States, Canada and Switzerland. Annie Guérin's co-authors include Eric Q. Wu, Martin Cloutier, Andrew P. Yu, Parvez Mulani, Patrick Gagnon‐Sanschagrin, Dominick Latrémouille-Viau, Irina Pivneva, Marjolaine Gauthier‐Loiselle, Roy Nitulescu and Mei Sheng Duh and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.
In The Last Decade
Annie Guérin
208 papers receiving 4.4k citations
Hit Papers
Peers
Annie Guérin
Philip Haycock United Kingdom
Lorene M. Nelson United States
Shehzad Basaria United States
Michael V. Holmes United Kingdom
David Gaist Denmark
Jie Zheng China
James Yarmolinsky United Kingdom
Ulla Feldt‐Rasmussen Denmark
Fabiola Del Greco M Italy
Nicholas L. Smith United States
Citations per year, relative to Annie Guérin Annie Guérin (= 1×)
peers
Philip Haycock
Countries citing papers authored by Annie Guérin
Since
Specialization
Citations
This map shows the geographic impact of Annie Guérin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annie Guérin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annie Guérin more than expected).
Fields of papers citing papers by Annie Guérin
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Annie Guérin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annie Guérin. The network helps show where Annie Guérin may publish in the future.
Co-authorship network of co-authors of Annie Guérin
This figure shows the co-authorship network connecting the top 25 collaborators of Annie Guérin. A scholar is included among the top collaborators of Annie Guérin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annie Guérin. Annie Guérin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Jesudian, Arun, et al.. (2025). Assessment of Access Barriers to Rifaximin Among Patients with Hepatic Encephalopathy Using Adjudicated Claims Data. Advances in Therapy. 42(6). 2739–2753.
2.
Grossberg, George T., Cynthia Willey, Christy R. Houle, et al.. (2025). Agitation in individuals with Alzheimer’s disease: An assessment of behaviors using the cohen-mansfield agitation inventory in community-dwellers and impact on caregiver experience. Dementia. 25(2). 421–442.
3.
Wong, Robert J., et al.. (2025). Real-World Trends and Future Projections of the Prevalence of Cirrhosis and Hepatic Encephalopathy Among Commercially and Medicare-Insured Adults in the United States. Clinical and Translational Gastroenterology. 16(5). e00823–e00823.
4.
Atallah, Ehab, David Wei, Dominick Latrémouille-Viau, et al.. (2025). Treatment with asciminib after a prior tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia. Leukemia Research. 157. 108089–108089.
5.
Gagnon‐Sanschagrin, Patrick, M. Davidson, Cynthia Willey, et al.. (2024). The economic impact of suboptimal treatment and treatment switch among patients with Crohn’s disease treated with a first-line biologic – A US retrospective claims database study. Journal of Medical Economics. 27(1). 931–940.
6.
Sharma, Prateek, Gary W. Falk, Menaka Bhor, et al.. (2023). Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States. Journal of health economics and outcomes research. 51–58.
7.
Sharma, Prateek, Gary W. Falk, Menaka Bhor, et al.. (2023). Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States. Journal of health economics and outcomes research. 10(1). 51–58.
8.
Gagnon‐Sanschagrin, Patrick, M. Davidson, Cynthia Willey, et al.. (2023). Su1137 SUBOPTIMAL TREATMENT IN PATIENTS WITH CROHN'S DISEASE USING BIOLOGICS. Gastroenterology. 164(6). S–541.
9.
Grossberg, George T., Annette Urganus, Jeff Schein, et al.. (2023). A real-world assessment of healthcare costs associated with agitation in Alzheimer’s dementia. Journal of Medical Economics. 27(1). 99–108.
10.
Jesudian, Arun, et al.. (2023). Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costs. Journal of Medical Economics. 26(1). 1169–1177.
11.
Schein, Jeff, et al.. (2022). Reasons for Treatment Changes in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Chart Review Study. Advances in Therapy. 39(12). 5487–5503.
12.
Schein, Jeffrey, Christy R. Houle, Annette Urganus, et al.. (2021). Prevalence of post-traumatic stress disorder in the United States: a systematic literature review. Current Medical Research and Opinion. 37(12). 2151–2161.
13.
Cloutier, Martin, Ameur M. Manceur, Annie Guérin, et al.. (2020). The societal economic burden of autosomal dominant polycystic kidney disease in the United States. BMC Health Services Research. 20(1). 126–126.
14.
Mukherjee, Sudipto, Xiting Cao, Rodrigo Maegawa, et al.. (2020). Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP). Blood. 136(Supplement 1). 17–18.
15.
Stein, Eytan M., Dominick Latrémouille-Viau, George J Joseph, et al.. (2019). Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis. Blood. 134(Supplement_1). 3495–3495.
16.
Kimball, Alexa B., Murali Sundaram, Martin Cloutier, et al.. (2018). Increased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based Analysis.. PubMed. 17(2). 180–186.
17.
Paller, Amy S., Rakesh Singh, Martin Cloutier, et al.. (2018). Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis.. PubMed. 17(2). 187–194.
18.
Ritchie, Ellen K., Dominick Latrémouille-Viau, Annie Guérin, et al.. (2017). Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in US Clinical Practice, with a Focus on Tyrosine Kinase Inhibitor Therapy Discontinuation. Blood. 130. 3396–3396.
19.
Li, Nanxin, et al.. (2016). Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2− metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis. Journal of Medical Economics. 19(4). 414–423.
20.
Yu, Andrew P., Annie Guérin, Karthik Ramakrishnan, et al.. (2011). Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. Journal of Medical Economics. 14(4). 486–496.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Philip Haycock Breakdown of academic impact, for papers by Lorene M. Nelson Breakdown of academic impact, for papers by Shehzad Basaria Breakdown of academic impact, for papers by Michael V. Holmes Breakdown of academic impact, for papers by David Gaist Breakdown of academic impact, for papers by Jie Zheng Breakdown of academic impact, for papers by James Yarmolinsky Breakdown of academic impact, for papers by Ulla Feldt‐Rasmussen Breakdown of academic impact, for papers by Fabiola Del Greco M Breakdown of academic impact, for papers by Nicholas L. Smith